Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03113500
Title Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

mature T-cell and NK-cell lymphoma

Therapies

Etoposide

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone

Doxorubicin

Cyclophosphamide

Prednisone

Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
BCCA-Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field